Introduction
Chimpanzees are 98% genetically identical to humans and were one of the first non-human primate species that were experimentally infected with HIV-1 in an attempt to develop an animal model for AIDS pathogenesis (Alter et al., 1984; Gendelman et al., 1991; Watanabe et al., 1991) . Early studies showed that certain strains of HIV-1 were capable of establishing a persistent infection in chimpanzees in vivo; however, all of these were T-cell-line-adapted viruses. In contrast, primary HIV-1 isolates generally failed to replicate in chimpanzee CD4+ T lymphocytes, and this was true in vitro as well as in vivo (Benton et al., 1999; Bogers et al., 1998; Gendelman et al., 1991; Pischinger et al., 1998; Schuitemaker et al., 1993; Shibata et al., 1995; Watanabe et al., 1991) . In fact, it was subsequently determined that all HIV-1 strains capable of replicating in chimpanzee PBMCs in vitro used the CXCR4 chemokine receptor for entry, either exclusively (X4) or as dual tropic (X4R5) strains (Cho et al., 1996; Schuitemaker et al., 1993; Shibata et al., 1995) . Conversely, HIV-1 primary isolates that were CCR5 tropic (R5) failed to establish a productive infection in chimpanzee PBMCs in vitro (Benton et al., 1999; Cho et al., 1996; Ondoa et al., 2002; Schuitemaker et al., 1993; Shibata et al., 1995) .
Collectively, these findings were taken to indicate that there was a coreceptor-dependent entry restriction for HIV-1 in chimpanzee cells.
The apparent replication block of R5 strains was difficult to reconcile with the subsequent observation that naturally occurring SIVcpz strains were all R5 tropic (Bibollet-Ruche et al., 2004; MullerTrutwin et al., 2000; Ondoa et al., 2001; Takehisa et al., 2007) . Moreover, R5 HIV-1 variants were subsequently identified, which were capable of establishing a persistent infection in vivo (Conley et al., 1996; ten Haaft et al., 2001) . Finally, human and chimpanzee CCR5 differ by only two amino acids, at position 13 (Asn in human, Asp in chimpanzee) and position 130 (Val in human, Ile in chimpanzee), and multiple studies have shown that these two positions are not involved in HIV-1 gp120 binding (Benton, Lee, and Kennedy, 1998; Dragic et al., 1998; Martin et al., 1997; Muller-Trutwin et al., 1999; Pretet et al., 1997; Samson et al., 1996; Zacharova, Zachar, and Goustin, 1997) . Survey of a large number of chimpanzees also failed to identify inactivating mutations of the CCR5 gene, such as the CCR5-Δ32 nonfunctional human allele (Martinson et al., 1997; Mummidi et al., 2000; ten Haaft et al., 1997; Voevodin, Samilchuk, and Dashti, 1998) . Together, these finding argued against a coreceptor-related entry block of R5 tropic HIV-1 in chimpanzees T lymphocytes.
The lack of replication of HIV-1 R5 isolates in chimpanzee T-cells could be explained by a differential CCR5 expression on in vitroactivated chimpanzee compared to human lymphocytes. A minimal CCR5 threshold appears to be required for efficient viral entry and this Virology 394 (2009) [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] threshold seems to be dependent on CD4 expression levels (Dejucq, Simmons, and Clapham, 1999; Lin et al., 2002; Platt et al., 1998) . CCR5 cell surface expression on activated human CD4+ lymphocytes varies considerably among different human donors, possibly because of polymorphisms in the CCR5 5′ cis-regulatory region Trkola et al., 1996; Wu et al., 1997) . Polymorphisms in the chimpanzee CCR5 5′ cis-regulatory region have been reported, distinct from the polymorphisms found in humans (Bamshad et al., 2002; Tang et al., 1999; Wooding et al., 2005) . CCR5 expression on human CD4+ T lymphocytes is known to be dependent on the degree of cellular activation, on memory versus naïve phenotypes of these cells and on the ligand used for polyclonal T-cell activation (Bleul et al., 1997; Mengozzi et al., 2001; Riley et al., 1998) . Indeed phytohemagglutinin (PHA), the mitogen used in most previous studies of chimpanzee PBMCs activation, is rather ineffective at inducing CCR5 cell surface expression in human CD4+ lymphocytes (Bleul et al., 1997) . The secretion of β-chemokines, such as CCL3 (MIP-1 alpha), CCL4 (MIP-1 beta) or CCL5 (RANTES), by chimpanzee T-cells could also account for the replication block of HIV-1 R5 strains in vitro. These β-chemokines can block infection either directly via blocking gp120-CD4 interaction or indirectly by inducing CCR5 internalization (Creson et al., 1999; Mack et al., 1998; Riley et al., 1997; Sabbe et al., 2001) . Consistent with this hypothesis, the gene copy number of the β-chemokine CCL3L1, a duplicated isoform of CCL3, was reported to be higher in chimpanzees compared to humans (Gonzalez et al., 2005; Shao et al., 2007) .
In this study, we asked whether the previously reported failure of R5 HIV-1 to replicate in chimpanzee CD4+ T-cell cultures might reflect an experimental artifact. Specifically, we asked whether different levels of T-cell activation could account for the observed replication differences, as the level of T-cell activation determines the level of HIV-1 replication. Our results show that this is indeed the case. Employing a novel lymphocyte activation protocol, we show that chimpanzee CD4+ T-cells can support efficient replication of prototypic R5 HIV-1 strains.
Results

Limited proliferation of chimpanzee CD4+ T lymphocytes under standard activation conditions
Standard lymphocyte activation protocols make use of a variety of agents such as lectins, enterotoxins or monoclonal antibodies that induce T-cell activation and proliferation via T-cell receptor crosslinking (Kruisbeek et al., 2004; Vicenzi and Poli, 2005) . In an initial set of experiments, we thus used phytohemagglutinin (PHA) to activate chimpanzee CD4+ T lymphocytes as previously described (Beaumont et al., 2000; Gendelman et al., 1991; Nguyen et al., 2006; Schuitemaker et al., 1993; Shibata et al., 1995; Watanabe et al., 1991) . Replication of the X4-tropic HIV-1 SG3 strain in these PHA-activated T-cell cultures was highly variable among chimpanzee donors (n = 8, day 8 post-infection median p24 = 13 ng/ml, range = 0-72 ng/ml), ranging from no replication (n = 2) to levels 10-fold lower compared to human donors (n = 6, day 8 post-infection median p24 = 193 ng/ ml, range = 120-430 ng/ml; Fig. 1A ). Although HIV-1 SG3 was specifically selected for its ability to efficiently replicate in chimpanzee T-cells (Ghosh et al., 1993) , lymphocytes from some chimpanzee donors were unable to support SG3 replication under these conditions. Moreover, the R5 strain YU2 did not replicate in any of the chimpanzee T-cell cultures following this standard protocol (data not shown). Similar results were obtained when chimpanzee CD4+ lymphocytes were stimulated with concanavalin A (data not shown). Flow cytometry analysis of PHA-stimulated cells identified activated CD4+ lymphocytes in both human and chimpanzee cultures, as shown by the appearance of larger cells with increased granularity (Fig. 1B) . However, trypan blue staining revealed two-to threefold lower numbers of viable cells in PHA-activated chimpanzee compared to human cultures. We thus explored conditions under which human and chimpanzee CD4+ lymphocytes would be activated and proliferate to the same extent and supporting HIV-1 replication.
We first evaluated a stimulation protocol using anti-CD3 or a combination of anti-CD3 + anti-CD28 monoclonal antibodies (mAbs), and the results were recently reported . We found that not all anti-CD3 mAb isotype were equally capable of stimulating chimpanzee T-cells. While immunological activation of chimpanzee lymphocytes was achieved with anti-CD3 mAbs of the IgG2a isotype, these activated cells still remained resistant to infection with the R5 tropic HIV-1 YU2 strain and less supportive of the X4-tropic HIV-1 SG3 replication compared to human lymphocytes activated under the same protocol.
We next tested the Staphylococcal enterotoxin B (SEB) superantigen activation competence of human and chimpanzee CD4+ lymphocytes. Previous studies demonstrated that bacterial superantigens such as SEB induce a more robust proliferative response in non-human primate T-cells, including macaque and chimpanzee, compared to lectin stimulation (Bavari et al., 1995; Kakimoto et al., 1999; Loffredo et al., 2004) . As with PHA, we found that cellular Fig. 1 . HIV-1 SG3 replication in PHA-activated chimpanzee and human CD4+ lymphocytes. (A) CD4+ lymphocytes from eight chimpanzees (C1 to C8) and six human (H1 to H6) donors were activated with PHA and tested for their ability to support HIV-1 SG3 replication. Infections were initiated at a multiplicity of infection (MOI) of 0.1. Virus replication was monitored by quantifying the p24 viral antigen in the culture supernatants on day 8 post-infection (y-axis, nanograms of p24 per ml of culture supernatant). The grey box indicates the cutoff (1 ng/ml) below which replication is considered negative. (B) Representative flow cytometric density plots (xaxis, electronic volume; y-axis, side scatter) of CD4+ lymphocytes at baseline (left panels) and 48 h post PHA activation (right panels) for human (top panels) and chimpanzee (lower panels). The percentage of activated cells located in gate R2 are indicated.
proliferation was reduced in chimpanzee compared to human CD4+ lymphocyte cultures. However, SEB stimulation increased HIV-1 SG3 replication in both chimpanzee and human CD4+ lymphocytes by 3-to 40-fold compared to PHA-activated cells ( Fig. 2A) . Although SEBstimulated chimpanzee CD4+ lymphocytes were still refractory to HIV-1 YU2, a fourfold growth increase was observed in SEB-activated human cells (Fig. 2B) . We thus selected SEB as the mitogen for all further studies.
Optimization of the activation protocol for chimpanzee CD4+ T lymphocytes
Original experiments aimed at deciphering the mode of action of mitogens, such as PHA or SEB, in respect to T-cell activation were performed in the presence of antigen presenting cells (APCs), including dendritic cells and macrophages (Bhardwaj et al., 1993; Boshell et al., 1996; Damaj et al., 1992; Hewitt et al., 1992; Mills et al., 1985; Spertini et al., 1991; Wakasugi et al., 1985) . We thus hypothesized that APCs, specifically macrophages, may provide additional signals, via direct cell-cell contact or cytokine production that could promote and sustain activation of chimpanzee T lymphocytes. To induce monocyte differentiation into macrophages, we supplemented the culture medium with 10% giant cell tumor conditioned medium, which contains M-CSF. Similar activation schemes using SEB-pulsed dendritic cells for the expansion of human CD4+ lymphocytes have recently been described (OswaldRichter et al., 2007; Unutmaz et al., 1999) . The results showed that chimpanzee, as well as human, CD4+ lymphocytes activated by SEB and cocultured in the presence of autologous monocyte-derived macrophages exhibit a strong and reproducible proliferative response.
Phenotypic characterization of activated lymphocytes
Differences in susceptibility to HIV-1 infection have been reported for various human lymphocyte populations, including naïve and memory T-cells, subsets of memory cells, as well as cells with T helper type 1 (Th1) or type 2 (Th2) phenotypes (Annunziato et al., 2000; Bonecchi et al., 1998; Cayota et al., 1993; Chun et al., 1997; OswaldRichter et al., 2007; Song et al., 2005b) . We thus determined the phenotype of the activated lymphocytes to ensure that HIV-1 replication in human and chimpanzee cultures was not biased by species-specific differences in the expanded T-cell populations.
For 16 chimpanzee and 7 human donors, activated CD4+ T-cells were analyzed for the expression of lymphocyte surface markers. Flow cytometric analyses were performed using monoclonal antibodies against human cell surface antigens known to cross-react with the cognate chimpanzee antigen. The expanded cells were CD3+ CD4+ with a reproducible purity of over 90% (data not shown). The cell surface markers expression profiles for representative human and chimpanzee are shown in Fig. 3 . The magnitude of expression for CD4, CD69, CD25, CCR5, CD28 and CD45RO was comparable between chimpanzees and humans (Fig. 4) . The mean fluorescence intensity of these markers on activated lymphocytes was not statistically significant between human and chimpanzees (p N 0.1) and showed limited inter-individual differences (data not shown). Expression of the CD69 and CD25 early and late activation markers, respectively, were comparable between human and chimpanzee. On average, N50% of the cells expressed CD25, indicative of an activated phenotype (Fig. 4) . The CXCR4, CD62L and CD45RA markers were consistently detected on chimpanzee T-cells, while their expression was lower or not detected on human T-cells (Figs. 3 and 4) . Significantly lower levels of HLA-DR expressing cells were detected in chimpanzee compared to human cultures (p = 0.0002). Further analysis of HLA-DR expression prior to activation revealed low expression on CD4+ lymphocytes and high expression on monocytes for both human and chimpanzee cultures (Fig. 5) . Thus, T-cell activation induced HLA-DR expression in human but not chimpanzee CD4+ lymphocytes (Fig. 5) . The HIV-1 coreceptor CCR5 was expressed at high levels in both species, while CXCR4 expression was significantly lower in humans (p =0.01; Figs. 3 and 4). Activated lymphocytes also expressed the CD45RO marker, indicating that the expanded cells were derived from the memory subset (Figs. 3 and 4) . Analysis of the CD45RO and CD45RA markers expression on CD4+ lymphocytes prior to stimulation revealed that naïve (CD45RA+) and memory (CD45RO+) subsets were equally represented (data not shown), indicating that our activation procedure preferentially induced the proliferation of CD4+ CD45RO+ memory lymphocytes. Low levels of the CD45RA marker were consistently detected on chimpanzee cells while not detected on human cells (p =0.0005; Figs. 3 and 4) . Cells from human donors expressed low to undetectable levels of the CD62L marker, while this marker was expressed at higher levels on chimpanzee Tcells (p = 0.0009; Figs. 3 and 4) . Upon stimulation, cell surface CD62L is hydrolyzed by metalloproteases and the low expression on human cells is likely due to degradation as no metalloproteinase inhibitors were included during the activation procedure or during the 24-h incubation in complete media (Kayagaki et al., 1995; Preece et al., 1996) . The CD62L expression detected on activated chimpanzee cells suggests a differential regulation of L-selectin between human and chimpanzees. Infections were initiated at a multiplicity of infection (MOI) of 0.1. Virus replication was monitored by quantifying the p24 viral antigen in the culture supernatants on day 8 post-infection (y-axis, nanograms of p24 per ml of culture supernatant). Virus replication was considered positive when the p24 antigen level reaches a cutoff value of 1 ng /ml (shaded box). For the three chimpanzee cultures, the median p24 level for the SG3 infections the in PHA-activated cells was 5.8 ng/ml and the median p24 in SEBactivated cells was 88.3 ng/ml.
We next monitored the production of interferon gamma (IFN-γ) and interleukin-4 (IL-4) by activated lymphocytes as markers for Th1 and Th2 subsets, respectively. No IL-4 production (detection limit 1 pg/ ml) and high level of IFN-γ were detected in both species. The average level IFN-γ in culture supernatant was 985 pg/ml (range = 77-2168, median = 898 pg/ml) and 968 pg/ml (range = 176-2877 pg/ml, median = 780 pg/ml) in human-and chimpanzee-activated CD4+ lymphocytes culture supernatants, respectively. The IFN-γ levels were not statistically different between species. These results indicate that the lymphocytes expanded under our protocol are predominantly from the Th1 subset.
Beta-chemokines secretion by activated lymphocytes
Although there was no significant difference in the number of CCR5 expressing cells between activated human and chimpanzee lymphocytes (Fig. 4) , a higher production of CCR5-binding chemokines (CCL5, CCL3, CCL4) by chimpanzee cells could theoretically block infection (Annunziato et al., 2000; Margolis et al., 1998; Trkola et al., 1998) . This possibility was of particular interest since chimpanzees were reported to have a higher copy number of the CCL3L1 gene, an isoform of the CCL3 chemokine (Gonzalez et al., 2005; Shao et al., 2007) . To test this hypothesis, we quantified the production of CCL5 and CCL3 (+CCL3L1 isoform as the Bio-Plex assay detects both chemokines) in the culture supernatants of activated lymphocytes. High levels of CCL5 were measured in both species and, surprisingly, a median 10-fold lower secretion of CCL3 was found in chimpanzee compared to human donors (Fig. 6) . The CCL3 expression Fig. 3 . Phenotype of activated human and chimpanzee lymphocytes. Activated CD4+ T-cells were stained and analyzed for cell surface activation (CD69, HLA-DR, CD25) and phenotypic (CD28, CD45RO, CD62L and CD45RA) markers expression as described in Materials and methods. Expression of the HIV-1 CD4 receptor as well as the CCR5 and CXCR4 coreceptors was also analyzed. Representative histogram profiles are shown for one human (left panels) and one chimpanzee (right panels) donor (x-axis: log fluorescence, y-axis: cell number). The electronic gate was set for the CD4+ lymphocyte population, and the percentage of cells expressing this maker were calculated using the same gate for all stains. differences were highly significant (p = 0.0002). These results indicate that a higher secretion of CCR5-binding cytokines by chimpanzee cells does not explain the reported replication block observed for R5 HIV-1 in chimpanzee lymphocytes.
SG3 and YU2 replication in chimpanzee CD4+ T lymphocytes
We next asked whether chimpanzee lymphocytes activated with the new protocol support HIV-1 replication, using the HIV-1 SG3 and YU2 prototypic strains. The results showed that both viruses replicated in T-cells from all chimpanzee donors tested. Mean p24 levels in the supernatants of SG3-and YU2-infected CD4+ lymphocytes of 23 chimpanzees at 7 days post-infection was 375 ng/ml (range = 74-2480 ng/ml, median = 374 ng/ml) and 33 ng/ml (range = 1-460 ng/ml, median = 40 ng/ml), respectively (Fig. 7A) . This profile was similar to the replication levels of these two viruses in human CD4+ T lymphocytes, although relative growth differences between SG3 and YU2 were less pronounced in human lymphocytes. The chimpanzee cultures exhibited a wider range of HIV-1 replication compared to human (Fig. 7B and 7C) , including five individuals with reduced YU2 replication (p24 b10 ng/ml; Fig. 7C ). This was not due to suboptimal activation as SG3 replicated efficiently in these same cultures (p24 values for SG3 at day 7 in these five chimpanzees: average = 488 ng/ml, range = 320-670 ng/ml, median = 550 ng/ml). These results thus showed that chimpanzee CD4+ T-cell cultures differed significantly more in their ability to replicate HIV-1 than human cultures, indicating significant intrinsic inter-individual differences among chimpanzee donors in supporting the replication various HIV-1 strains.
Susceptibility of chimpanzee CD4+ T lymphocytes to primary HIV-1 isolates
To validate the SG3 and YU2 isolates replication results, we next analyzed the replication of the HIV-1 R5 prototypic strains ADA, BaL and JRCSF in activated CD4+ lymphocytes from four human and chimpanzee donors. All strains replicated efficiently and with comparable replication kinetics in activated human T-cells (Fig. 8A) . Conversely, the BaL isolate replicated efficiently in chimpanzee cells to levels comparable to the SG3 and YU2 prototypic strains. The ADA strain typically exhibited lower replication levels and, unexpectedly, the JRCSF strain did not replicate in CD4+ lymphocytes from any of the chimpanzee donor tested (Fig. 8B) .
Taken together, these results indicate that the previously reported failure of R5 HIV-1 to replicate in chimpanzee T-cells was due, at least in part, to inadequate T-cell activation but also suggest that chimpanzee donors differ in their susceptibility to HIV-1 infection or that some human-adapted HIV-1 strains can be restricted for replication in chimpanzee cells.
Discussion
In this study, we investigated the replication potential of R5 and X4 HIV-1 strains in human and chimpanzee lymphocytes. We show that efficient and reproducible activation of chimpanzee CD4+ lymphocytes can be achieved in the presence of SEB and autologous macrophages, and that this mode of activation renders chimpanzee T-cells capable of supporting the replication of both prototypic X4 and R5 tropic HIV-1 strains. Characterization of activated T-cell also revealed differences in surface marker between human and chimpanzee, expanding previously reported species-specific differences of cell surface protein expression.
In the past, investigators screened chimpanzees by in vitro culture to find those most susceptible to HIV-1 infection (Eichberg et al., 1987; Nguyen et al., 2006; Pischinger et al., 1998; Schuitemaker et al., 1993; Shibata et al., 1995) ; however, the level of T-cell activation in these experiments was not determined. A more recent study noted differences in the proliferative response between human and chimpanzee T-cells (Nguyen et al., 2006) . This suggested that chimpanzee lymphocytes might require different activation stimuli than human lymphocytes to support HIV-1 replication. We reasoned that autologous macrophages might provide signals that would induce a longer lasting and/or more robust activation state. We found that the presence of differentiated macrophages early in the activation process was indeed the key since it facilitated sustained SEB-induced CD4+ lymphocyte proliferation, a function not provided by monocytes or B-lymphocytes in this system (FB-R, unpublished).
Chimpanzee CD4+ lymphocytes activated under the new protocol supported efficient replication of the prototypic R5 YU2 strain, revealing for the first time that the previously reported R5 replication block was likely a tissue culture artifact (Beaumont et al., 2000; Cho et al., 1996; Schuitemaker et al., 1993; Shibata et al., 1995) . We did, however, find that lymphocytes from different chimpanzee donors varied in their ability to support YU2 replication, more so than comparable human cultures ( Fig. 7B and C) . This was not due to lymphocyte activation levels, coreceptor expression or availability of target cells and may thus reflect as yet unidentified host factors that influence viral replication. The mechanisms underlying these differences among chimpanzee donors remain to be explored.
The phenotypic characterization of CD4+ lymphocytes activated under the new protocol also revealed species-specific differences in the expression of surface marker possibly linked to the regulation of T-cell activation. Because human and chimpanzee monocytes express comparable levels of HLA-DR, the low level of HLA-DR expression on activated chimpanzee CD4+ lymphocytes (Fig. 4) suggests that these cells might be less functional as APCs in vivo compared to their human counterpart. The role of MHC class II expression on CD4+ lymphocytes remain unclear, but several reports suggest that the MHC class II-mediated interaction between T-cells could regulate adaptive immune responses (Barnaba et al., 1994; Fischer et al., 2007; LaSalle et al., 1991) . In addition, MHC class II proteins differ in their ability to bind superantigens such as SEB and amino acid differences between human and chimpanzee MHC class II have been described (de Groot and Bontrop, 1999; Herman et al., 1990; Herrmann et al., 1989 ). Thus, it is possible that differences in HLA-DR cell surface expression and/or allelic polymorphism (via differences in SEB affinity) account for the limited proliferative response of chimpanzee CD4+ lymphocytes to SEB stimulation in the absence of macrophages. Activated chimpanzee CD4+ lymphocytes also expressed high levels of the CD62L homing Fig. 8 . Primary HIV-1 strains YU2, JRCSF, ADA and BaL replication kinetics in human and chimpanzee CD4+ lymphocytes. Virus replication was monitored by measuring the level of the p24 antigen in culture supernatants. Replication curves for each strain are shown as the average of independent experiments in CD4+ T lymphocytes from four different chimpanzee and human donors; the error bars represent one standard deviation calculated for each time point. The grey box indicate the cutoff (1 ng/ml) below which replication is considered negative.
receptor, which adds to the list of adhesion molecules involved in costimulatory receptor/ligand interactions, including CD33-related Siglecs (Nguyen et al., 2006) , ICAMs (Walter et al., 2005 ) that could differentially modulate CD4+ lymphocyte activation and proliferation in vitro and in vivo. The basis of these differences between these two species, as well as their relevance to in vivo functional differences, will require further exploration.
In summary, we report here a new activation protocol that renders chimpanzee CD4 T-cells capable of replicating R5 tropic HIV-1 strains. This activation protocol has already proven useful to assess the biological relevance of an HIV-1 matrix protein adaptive change selected upon cross-species transmission of SIVcpz to humans and to analyze the replication potential of novel fecal-consensus SIVcpz and SIVgor molecular clones in chimpanzee CD4+ lymphocytes (Takehisa et al., 2009; Takehisa et al., 2007; Wain et al., 2007) . However, unanswered questions remain. We show here that chimpanzee donors vary significantly in the level of HIV-1 replication, much more so than human donors. The receptor and coreceptor expression levels are equivalent between human and chimpanzees (Fig. 4) ; thus, it seems improbable that, like natural SIV hosts such as sooty mangabeys and African green monkeys (Beaumier et al., 2009; Sodora et al., 2009) , CD4 or CCR5 expression differences account for the susceptibility differences. Moreover, we have recently identified additional HIV-1 strains and primary isolates that, similar to JRSCF, do not replicate in chimpanzee lymphocytes, including strains that use CXCR4 as coreceptor. These results point to chimpanzee-specific host factors can may block or modulate HIV-1 replication in chimpanzee lymphocytes. These restriction factors are likely different from currently know human HIV-1 restriction factors such as TRIM5a, APOBEC3G, since the human and chimpanzee alleles seem equivalent with respect to their anti-HIV-1 function (Kratovac et al., 2008; Sawyer et al., 2004; Song et al., 2005a) . Our new lymphocyte activation approach provides the basis for comparative studies of human and chimpanzee susceptibility to HIV-1 that could lead to the identification of novel host factors that control or are required for HIV-1 replication.
Materials and methods
Chimpanzee and human blood
Blood samples were collected from captive chimpanzees housed at the Yerkes Primate Research Center during their annual health survey, a procedure approved by the Emory Institutional Animal Care and Use Committee. None of the chimpanzees studied were infected with HIV-1 or SIVcpz. Human blood from healthy HIV-1-negative individuals was obtained from Research Blood Components (Boston, MA). Blood samples, collected using ACD as anticoagulant, were processed within 24 h.
Isolation of CD4+ cells
Chimpanzee and human peripheral blood mononuclear cells (PBMCs) were isolated by density separation using Ficoll-Hypaque Plus (GE-Healthcare, Piscataway, NJ) and centrifuged at 1800 rpm for 25 min at 22°C. Interphase mononuclear cells were washed once at room temperature in Hanks balanced saline solution (HBSS) + 4 mM EDTA and once at 4°C in HBSS + 1% FCS. CD4+ cells were purified from total PBMCs by positive selection using magnetic MicroBeads and an autoMACS™ (Miltenyi Biotec, Auburn, CA). Human CD4 MicroBeads were used for human and non-human primate CD4 MicroBeads for chimpanzee, according to manufacturer's protocols and recommendations. Purity of the CD4+ population was determined to be N90% by flow cytometric analysis.
Standard CD4+ T lymphocyte activation
Five to ten million CD4+ mononuclear cells (monocytes and lymphocytes) in 3 ml of RPMI media + 15% FCS were placed in one well of a 6-well plate in the presence of PHA (PHA-P; Sigma-Aldridge, St. Louis, MO) (3 μg/ml) or Staphylococcal enterotoxin B (SEB; SigmaAldridge) (3 μg/ml) for 48 to 72 h at 37°C in a 5% CO 2 incubator. Following activation, cells were cultured at 1 × 10 6 /ml and infected in complete media (RPMI + 10% FBS with 30 U/ml of IL-2; Roche Diagnostics).
Improved CD4+ T lymphocyte activation
Briefly, the optimized activation procedure can be divided in three steps: (i) to enable efficient lymphocyte activation and proliferation, the ratio of monocytes to lymphocytes in the CD4+ positively selected cell fraction is changed from 1:10 to about 1:2 by successive plating; (ii) monocytes are pulsed overnight with SEB; and (iii) upon monocyte differentiation in macrophages, CD4+ lymphocytes are allowed to proliferate for 6 to 7 days. For the first step, 20 to 40 million CD4+ mononuclear cells (monocytes and lymphocytes) were plated in 2 ml of serum-free RPMI media in one well of a 6-well plate for 30 min at 37°C in a 5% CO 2 incubator. Cells were allowed to adhere, and non-adherent cells were subsequently placed into a new well. This procedure was repeated a total of three times to increase the ratio of adherent monocyte/macrophages (10-25% of the initial cells) to non-adherent CD4+ T lymphocytes (Koller et al., 1973) . For the second step, monocytes and lymphocytes were pulsed for 12-15 h with 3 μg/ml of SEB in 1.5 ml RPMI + 15% FCS. For the third step, SEB was removed by media exchange and washing non-adherent cells with HBSS, monocytes were differentiated in 2.5 ml of DMEM with 10% giant cell tumor conditioned medium (BioVeris Corp., Gaithersburg, MD) and 10% Human AB serum (Fisher Bioreagents, Fair Lawn, NJ); lymphocytes were then allowed to proliferate for 6-7 days. During this time, an additional 2 ml of the same media was added to each well to sustain lymphocyte proliferation. Combining nonadherent cells from all wells, 30-40 million activated CD4+ lymphocytes were typically harvested by days 6-7. Following proliferation, cells were cultured at a density of 1 × 10 6 /ml in complete media (DMEM + 10% FBS with 30 U/ml of IL-2; Roche Diagnostics) for 24 h prior to infection. Culturing the cells in complete media for at least 24 h prior to infection increased the activated cells susceptibility to HIV-1 infection (data not shown). Once activated, CD4+ lymphocytes continued to proliferate in complete media in the absence of further stimuli for at least 2 weeks.
Immunofluorescent staining and flow cytometric analysis
Activated T-cells were transferred in staining buffer (PBS + 2% FBS + 0.2% sodium azide), and the following conjugated monoclonal antibodies against human differentiation antigens were used to determine the cell surface expression of the corresponding markers (clone number indicated in parenthesis): anti-CD3 (UCHT1), anti-CD8 (RPA-T8), anti-CD4 (RPA-T4), anti-CD69 (FN50), anti-HLA-DR (G46-6), anti-CD25 (M-A251), anti-CD45RO (UCHL1), anti-CD45RA (HI100), anti-CD62L (Dreg 56), anti-CD184 (12G5), all from BD Biosciences (San Jose, CA) and anti-CD195 (CTC5) from R&D Systems Inc. (Minneapolis, MN) . Stained cells were analyzed on a Cell Lab Quanta™ SC MPL flow cytometer (Beckman Coulter, Fullerton, CA) and a minimum of 10,000 events per three-color stain were collected. Matching antibody isotype control stains were included as negative controls for each antibody combination in all runs. Results were analyzed using Cell Lab Quanta™ software (Beckman Coulter) and CellQuest™ Pro (BD Biosciences).
Viruses and virus stocks
HIV-1 SG3, YU2, JRCSF and ADA virus stocks were generated by transfecting the respective full-length molecular clone into 293T cells using FuGene 6 (Roche Applied Science, Indianapolis, IN) according to manufacturer's protocol. Forty-eight to seventy-two hours posttransfection, culture supernatants were harvested, clarified by low speed centrifugation, and aliquots were stored at − 70°C. The HIV-1 Bal isolate was obtained from the NIH AIDS Research and Reference Reagent Program and propagated on SEB-activated human CD4+ lymphocytes to generate virus stock. Culture supernatants were harvested, clarified by low speed centrifugation, and aliquots were stored at −70°C. Infectious titers of virus stocks were determined using the JC53BL assay as described previously (Derdeyn et al., 2000; Wei et al., 2002) .
Infection and replication kinetics
Chimpanzee-and human-activated CD4+ T lymphocytes (0.5 10 6 /vial) were infected overnight at a multiplicity of infection (MOI) of 0.1 (based on JC53BL infectious titer) in 300 μl of complete media. Overnight incubation in this small volume was necessary for optimal infection of chimpanzee lymphocytes. After 12-15 h, cells were washed three times with HBSS medium and plated in a well of a 24-well plate in 2 ml of complete media. Forty microliters of supernatant was collected every 2-3 days and stored at −70°C. To monitor virus replication, the p24 viral antigen was quantified in the culture supernatants using the HIV-1 p24 antigen EIA kit according to the manufacturer's protocol (Beckman Coulter).
Bio-Plex™ cytokine assay
Activated lymphocytes culture supernatants were collected after 24 h incubation in complete media and stored at −70°C. Cytokines concentration for IL-4, IFN-γ, CCL3 and CCL5 were determined from 50 μl of supernatant using the corresponding Bio-Plex™ Human Cytokine Assay according to manufacturer's protocol (Bio-Rad Laboratories, Hercules, CA). Data were collected using a Bio-Plex™ 200 suspension array system (Bio-Rad Laboratories), and statistical analyses of the results were performed using Prism software version 4.0c for Macintosh (GraphPad Software Inc.).
Statistical analyses
The nonparametric Mann-Whitney U test (two-tailed) was used to analyze the cell surface markers expression and cytokine production differences between chimpanzee and human donors. Differences in expression between the two groups were considered significant when p values were ≤0.01. Correlation analysis for the HIV-1 SG3 and YU2 replication in activated chimpanzee T-cells was performed using the Spearman's rank correlation test. These statistical analyses were performed using Prism software version 4.0c for Macintosh (GraphPad Software Inc.).
